Krystal Biotech KRYS underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below ...

Portage Biotech's PORT-7 showed >90% tumor growth inhibition with anti-PD1 combo in a murine mesothelioma model. PORT-7 single-agent activity outperformed anti-PD1 treatment alone; first-in-human ...

The Food and Drug Administration is projecting a more favorable stance toward biotech, emphasizing streamlined processes and accelerated approvals (“FDA Sends a Bullish Signal to Biotech ...

Radiopharma biotech Cellectar Biosciences is seeking strategic alternatives, opening the door to further opportunities after looking to partner off its sole clinical-stage asset to no avail this ...

Octagon Therapeutics has thrown in the towel. The Novo Nordisk-allied autoimmune disease biotech is winding down after deprioritizing its lead program and running into unresolved biology questions.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation ...

China’s WuXi AppTec, which a US legislative commission called the “Huawei equivalent for biotechnology”, has reported a surge in US business despite increased scrutiny from Washington ...

Kane Biotech's December 31, 2024 Financial Statements and the Management Discussion and Analysis with regards thereto are now available on SEDAR+ and the Company's website. Management believes that ...

the Rahway-based company announced April 29. The Merck Wilmington Biotech facility will house laboratory, manufacturing and warehouse capabilities for the launch and commercial production of ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer ...